Prenat Diagn by Ailes, Elizabeth C. et al.
Prenatal Diagnosis of Non-Syndromic Congenital Heart Defects
Elizabeth C. Ailes1,2,*, Suzanne M. Gilboa1, Tiffany Riehle-Colarusso1, Candice Y. 
Johnson1, Charlotte A. Hobbs3, Adolfo Correa4, Margaret A. Honein1, and the National 
Birth Defects Prevention Study
1National Center on Birth Defects and Developmental Disabilities; CDC; Atlanta, Georgia, USA
2Epidemic Intelligence Service, Office of Surveillance, Epidemiology and Laboratory Services, 
CDC; Atlanta, Georgia, USA
3College of Medicine, University of Arkansas for Medical Sciences; Little Rock, Arkansas, USA
4
 Department of Medicine, University of Mississippi Medical Center; Jackson, Mississippi, USA
Abstract
Objectives—Congenital heart defects (CHDs) occur in nearly 1% of live births. We sought to 
assess factors associated with prenatal CHD diagnosis in the National Birth Defects Prevention 
Study (NBDPS).
Methods—We analyzed data from mothers with CHD-affected pregnancies from 1998–2005. 
Prenatal CHD diagnosis was defined as affirmative responses to questions about abnormal 
prenatal ultrasounds and/or fetal echocardiography obtained during a structured telephone 
interview.
Results—Fifteen percent (1,097/7,299) of women with CHD-affected pregnancies (excluding 
recognized syndromes and single-gene disorders) reported receiving a prenatal CHD diagnosis. 
Prenatal CHD diagnosis was positively associated with advanced maternal age, family history of 
CHD, type 1 or type 2 diabetes, twin or higher order gestation, CHD complexity and presence of 
extracardiac defects. Prenatal CHD diagnosis was inversely associated with maternal Hispanic 
race/ethnicity, prepregnancy overweight or obesity, and pre-existing hypertension. Prenatal CHD 
diagnosis varied by time to NBDPS interview and NBDPS study site.
Conclusions—Further work is warranted to identify reasons for the observed variability in 
maternal reports of prenatal CHD diagnosis and the extent to which differences in health literacy 
or health system factors such as access to specialized prenatal care and/or fetal echocardiography 
may account for such variability.
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INTRODUCTION
Congenital heart defects (CHDs) occur in nearly 1% of live births1, 2 and are associated with 
substantial morbidity and mortality.3, 4 Prenatal diagnosis of heart defects can lead to 
changes in medical management that may improve clinical outcomes. For example, 
decisions to deliver at tertiary care centers with ready access to pediatric medical and 
surgical specialties are associated with decreased neonatal morbidity and mortality.5 
Prenatal diagnosis can be particularly important in the case of critical CHDs (those that 
require surgery or catheterization within the first year of life) that may cause hypoxia and 
lead to severe organ damage or death in the absence of timely intervention.6-8 Although 
several risk factors for CHDs have been identified, such as family history, exposure to 
teratogenic medications, lack of prenatal vitamin and folic acid use, prepregnancy obesity, 
and pregestational diabetes, the causes of the majority of CHDs remain unexplained.9
In the United States, prenatal diagnosis rates for CHDs vary by type, and ranged from 6% 
during 1990-1994 to 36% during 2004-2005 and 39% during 1997-2007 in select 
populations.10-12 The American Institute of Ultrasound in Medicine (AUIM) recommends 
that pregnant women receive a second or third trimester ultrasound during which 
sonographers conduct basic cardiac examinations including a four-chamber view of the heart 
and, when technically feasible, views of the outflow tracts.13 Indications for fetal 
echocardiography include, but are not limited to: 1) an abnormal routine ultrasound; 2) a 
family history of CHD; 3) pregestational diabetes; or 4) a pregnancy conceived by in vitro 
fertilization.14 Reports on the variability of prenatal diagnosis rates for CHD in the U.S. and 
possible correlates of such variability are limited. The objectives of this study were to use 
data from mothers of CHD-affected pregnancies enrolled in the National Birth Defects 
Prevention Study (NBDPS) to estimate the proportion of mothers of infants with non-
syndromic CHDs who report receiving a prenatal diagnosis and to investigate maternal and 
infant characteristics associated with maternal report of prenatal diagnosis.
METHODS
Study Population
The NBDPS is an on-going population-based case-control study of risk factors for selected 
major birth defects. The NBDPS enrolled pregnant women with dates of delivery on or after 
October 1, 1997 and we limited this analysis to infants with an estimated date of delivery 
(EDD) from January 1, 1998 to December 31, 2005. The 10 study sites include: the states of 
Arkansas (since 1998), Iowa, New Jersey (1998-2002 only), and Utah (since 2003) and 
select counties in California (Central Valley counties), Georgia (metropolitan Atlanta 
counties), Massachusetts (eastern counties, including the Boston metropolitan area), North 
Carolina (northern Piedmont region counties, since 2003), New York (Western New York, 
Lower Hudson Valley counties), and Texas (Lower Rio Grande Valley counties). The study 
methodology has been described previously.15 Briefly, NBDPS cases include live-born 
infants (all sites), stillbirths of ≥20 weeks gestation (all sites except NY before the year 2000 
and NJ), and elective terminations ≥20 weeks gestation (all sites except NY before the year 
2000, MA, and NJ). Controls are live-born infants without any major birth defects and are 
Ailes et al. Page 2
Prenat Diagn. Author manuscript; available in PMC 2015 June 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
randomly selected from vital records or hospital discharge information from the same 
catchment areas from which cases were selected.
Clinical Review of CHD Cases
Medical records from all fetuses/infants with CHDs were reviewed by trained abstractors as 
part of the surveillance systems in each contributing study center. Fetuses/infants with 
documentation of major chromosomal abnormalities, single-gene disorders and birth defects 
with known etiology are excluded from the NBDPS which means the exclusion of those 
with an identified 22q11 deletion. Furthermore, for a CHD case to be included in the 
NBDPS, diagnosis of the CHD must be confirmed by echocardiography, cardiac 
catheterization, surgery, or autopsy.15 Cases with only a clinical diagnosis recorded in their 
medical record, such as diagnoses using only physical exam, chest radiography, or 
electrocardiogram, were not considered to have a definitive diagnosis and were excluded 
from NBDPS. Prenatally diagnosed and terminated pregnancies at any gestational age are 
included if there was a postmortem examination to confirm the defect or if the prenatal 
examination was done by a pediatric cardiologist or at a prenatal diagnosis center with 
expertise in pediatric cardiology.16 Medical records abstractions for all potential CHD cases 
were reviewed and their heart defects were categorized by a physician with specialized 
training in pediatric cardiology. The complexity of each case was determined; cases with 
either a single heart defect or well-defined constellation of heart defects such as hypoplastic 
left heart syndrome or tetralogy of Fallot were categorized as having a simple heart defect; 
cases with more than one distinct heart defect, such as aortic stenosis with coarctation of the 
aorta, heterotaxy, or single ventricle, were categorized as having an association or complex 
heart defect.16 Each case was also categorized according to whether extracardiac defects 
(defect(s) in an organ other than the heart) were present; cases with no extracardiac defects 
were categorized as isolated.
Reporting of Prenatal Diagnosis
The NBDPS does not specifically ascertain the date of initial diagnosis from medical 
records; rather, the study systematically ascertains the dates and results from 
echocardiography, catheterization, surgery or autopsy reports documentation required to 
confirm the CHD diagnosis for inclusion in the study. We therefore decided not to use these 
clinical data elements to estimate the frequency of prenatal CHD diagnosis, knowing that 
prenatal procedures were likely to be under-reported. Rather, we relied on maternal self-
report during the standardized computer-assisted telephone interview (CATI) that was 
administered in English or Spanish by a trained interviewer six weeks to two years after the 
EDD. In addition to being asked a wide range of questions about lifestyle, medical, 
nutritional, and occupational exposures, mothers were also asked several questions about 
their prenatal care. In this analysis, we used two interview questions to define maternal 
report of a prenatal CHD diagnosis. Diagnoses based on abnormal ultrasounds were derived 
from the question “Did you have any ultrasounds which showed any abnormalities with the 
fetus, placenta or fluid?” The description of the abnormality(ies) found, and the date or 
timing during pregnancy (week, month or trimester) of abnormal ultrasounds were obtained. 
Prenatal diagnoses based on fetal echocardiography were derived from the question “Did 
you have any prenatal diagnostic tests such as fetal echocardiography or fetal dye studies?” 
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The type of test performed, the description of the abnormality(ies) found, and the date or 
timing during pregnancy (week, month or trimester) of the test for each abnormal fetal 
echocardiography were recorded.
Unique verbatim descriptions of abnormal ultrasounds and fetal echocardiography from case 
and control women were categorized (3,271 unique descriptions). A study team member 
with expertise in pediatric cardiology reviewed all prenatal ultrasound and fetal 
echocardiography descriptions to determine whether the description represented a prenatal 
diagnosis of a CHD (“strongly indicative of a CHD”, “weakly indicative of a CHD” or “not 
indicative of a CHD”). Specific descriptions such as “tetralogy of Fallot” or “hypoplastic 
left heart syndrome” were categorized as “strongly indicative of a CHD” while more vague 
descriptions that may indicate the presence of a CHD such as “heart problem” were 
evaluated as “weakly indicative of a CHD”. A woman was categorized as reporting a 
prenatal CHD diagnosis if she reported having an ultrasound or fetal echocardiography that 
detected an abnormality assessed as “weakly” or “strongly” indicative of a CHD before the 
date of birth. Mothers who reported having either test but were missing data on the timing of 
the test during pregnancy were excluded. Mothers who reported having either test but 
reported dates after the baby's date of birth were categorized as not having a prenatal 
diagnosis.
Data Analysis
We excluded mothers of CHD-affected pregnancies who resided in New Jersey (for all 
years), and those who resided in Texas before June 1998 because during these time periods 
only a sample of infants from among all clinically-eligible fetuses/infants with CHDs were 
enrolled in the NBDPS. For all other time periods, there was no sampling of CHD types by 
study personnel and all interviewed mothers of CHD-affected pregnancies that met the 
NBDPS case definition were included in the NBDPS. Our final sample included mothers 
who reported receiving prenatal care and who could recall the timing of their abnormal 
ultrasound or fetal echocardiography.
We explored factors posited a priori to be associated with the report of a prenatal diagnosis, 
including the type of CHD, complexity of CHD, presence of extracardiac defects, year of 
estimated date of delivery, first degree family history of CHD, gestational age, plurality, 
maternal race/ethnicity, maternal age at delivery, maternal level of education, maternal 
prepregnancy body mass index (BMI), maternal pregestational diabetes, maternal diagnosis 
of hypertension, maternal fertility treatments, number of pregnancy losses before this 
pregnancy, pregnancy intention, trimester of first prenatal care visit, time from EDD to 
NBDPS interview, and NBDPS study site. We used the following categories for gestational 
age (very preterm [<32 completed weeks), preterm [32–36 completed weeks), or term [≥ 37 
completed weeks)), plurality (singleton or multiple), maternal race/ethnicity (non-Hispanic 
white, non-Hispanic black, Hispanic, or Other), maternal age at delivery (<30 years or >=30 
years), maternal level of education (0-12 years or >12 years of education), prepregnancy 
BMI (underweight [<18.5 kg/m2), normal weight [18.5–<25.0 kg/m2), overweight [25.0–
<30.0 kg/m2), or obese [≥30.0 kg/m2)), pregestational diabetes (none, type 1, or type 2), 
number of pregnancy losses before this pregnancy (none, one, two, or more than two losses), 
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pregnancy intention (intended, mistimed/ambivalent, or unwanted17), and time to interview 
(6 weeks-6 months, 7-12 months, 13-18 months, and 19-24 months18). Data on CHD type, 
CHD complexity, presence of extracardiac defects, gestational age and study site came from 
previously abstracted medical records. All other variables included in the analyses were 
based on self-report during structured interviews.
We examined the frequency of maternal report of prenatal diagnosis according to the 
aforementioned factors. We also examined frequencies by the joint distribution of study site 
and CHD type. However, because of unstable estimates in smaller strata, we only present the 
frequencies for CHD types with ≥ 300 simple, isolated cases and >10% maternal report of 
prenatal diagnosis. We used bivariate and multivariable Poisson regression models with a 
“sandwich” or robust covariance matrix estimator to calculate crude and adjusted prevalence 
ratios (cPR, aPR) and corresponding 95% confidence intervals (95% CIs).19 This model was 
chosen because, unlike logistic regression models, the Poisson regression model with robust 
error estimator can provide an unbiased estimate of the prevalence ratio when the outcome 
under study (in this case, the frequency of maternal reported prenatal CHD diagnosis) is not 
“rare”.20 Although robust error estimators are typically used with clustered data, they are 
used in this context with uncorrelated data to account for the overestimation of the variance 
that can occur when modeling binary data with Poisson regression.20 All factors, with the 
exception of CHD type, were included in the multivariable model. Reference values for 
variables were determined a priori, with the exception of study site, for which the NBDPS 
site with the lowest frequency of maternal report of prenatal detection and sufficient sample 
size was selected as the referent. All significance tests used a two-sided alpha of 0.05 and all 
analyses were conducted using SAS v.9.2 (SAS Institute Inc., Cary, NC). This study was 
approved by the Centers for Disease Control and Prevention's and study centers’ 
Institutional Review Boards.
RESULTS
There were 7,971 mothers with non-syndromic CHD-affected pregnancies with EDDs from 
January 1998–December 2005. After excluding mothers who resided in New Jersey 
(n=548), those who resided in Texas and had EDDs before June, 1998 (n=10), those with 
unknown or no prenatal care (n=90), and those with missing dates of abnormal ultrasounds 
or fetal echocardiography (n=24), 7,299 mothers (91.6%) were eligible for further analysis. 
Almost all fetuses/infants (n=7,230; 99.1%) were live-born, 74.4% (n=5,404) had simple 
heart defects, and 83.6% (n=6,104) had no extracardiac defects.
Of the 7,299 mothers with CHD-affected pregnancies, 1,097 (15.0%) reported having an 
abnormal ultrasound or fetal echocardiography that suggested a CHD, the majority of which 
(n=1,011; 92.2%) were assessed as being “strongly” indicative of a CHD. Among those with 
simple, isolated defects, maternal report of prenatal diagnosis varied by CHD type, from 
0.8% for total anomalous pulmonary venous return to 52.9% for hypoplastic left heart 
syndrome (HLHS) (Figure 1). There was also substantial variability by NBDPS study site; 
maternal report of prenatal CHD diagnosis ranged from 7.1% to 25.6% by site (Table). In 
addition, there was substantial variability by site within CHD types. Among isolated cases of 
HLHS, maternal report ranged from 21.1–80.6% and other CHD types exhibited similar 
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variation as well (Figure 2). Maternal report of prenatal CHD diagnosis ranged from 12.7% 
in 1998 to 17.1% in 2002 though there was no evidence of a temporal trend (Table), even 
after accounting for changes in study site catchment area over time (data not shown).
Factors significantly associated with maternal reports of a prenatal CHD diagnosis in 
multivariable analyses included CHD complexity, presence of extracardiac defects, maternal 
factors such as advanced age (≥ 30 years), family history of CHD, type 1 diabetes, type 2 
diabetes, and twins or higher order gestation, as well as NBDPS study site. Factors such as 
maternal Hispanic race/ethnicity (compared to non-Hispanic white race/ethnicity), 
prepregnancy overweight (25.0–<30.0 kg/m2) or obese (≥ 30 kg/m2) BMI, pre-existing 
hypertension and NBDPS interview at 7-12 months, 13-18 months, and 19-24 months post-
EDD (compared to those interviewed at 6 weeks-6 months after their EDD) were each 
inversely associated with maternal report of prenatal diagnosis (Table).
DISCUSSION
In our study, 15% of mothers with non-syndromic CHD-affected pregnancies reported 
receiving a prenatal diagnosis. Maternal report of prenatal CHD diagnosis varied by NBDPS 
study site as well as by maternal characteristics such as plurality, race/ethnicity, age, 
presence of comorbid conditions (i.e., diabetes and obesity), and family history of CHD, and 
by the complexity of the CHD, presence of extracardiac defects, and CHD type.
Many of the characteristics associated with maternal report of prenatal CHD diagnosis are 
plausible given their likelihood to cause a woman's pregnancy to be closely monitored, such 
as family history of CHD, twin or a higher order gestation, presence of type 1 or type 2 
diabetes, and older maternal age.14, 21 In our study, overweight and obese mothers were 
each significantly less likely to have a prenatal CHD diagnosis than those in the normal 
prepregnancy weight BMI category. Maternal BMI has been found to be associated with 
lower prenatal diagnosis rates22, 23 and higher false positive rates23 for CHDs in some 
studies, but not others.12, 24 Detection might be more difficult in women with higher BMIs 
because of the increased layer of fat that limits the ability of ultrasound or echocardiography 
to visualize fetal structures, as has been found with prenatal detection of orofacial clefts.25
The prevalence of maternally-reported prenatal CHD diagnosis in our study varied 
significantly by CHD type, which is consistent with previous studies.2, 5, 12, 24, 26 Pinto et 
al.'s (2012) study in Utah from 1997-2007 found the prevalence of prenatal CHD diagnosis 
ranged from 0% for interrupted aortic arch type B to 100% for single ventricle, not 
otherwise specified, and three of the four defects most likely to be detected prenatally were 
considered to exhibit an abnormal four-chamber view (e.g., HLHS and atrioventricular 
septal defects). However, defects categorized as exhibiting abnormal outflow tracts or other 
abnormal views (e.g., coarctation of the aorta) tended to have lower rates of prenatal 
diagnosis,12 similar to what was seen in our study. These findings are not unexpected given 
the difficulty of detecting outflow tract obstruction defects via ultrasound. We also found 
increasing maternally-reported prenatal CHD diagnosis with increasing defect complexity 
(more than one heart defect), and the presence of extracardiac defects; studies of prenatal 
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diagnosis of CHDs12 and other types of birth defects25 have similarly found increased 
prenatal diagnosis when multiple birth defects were present.
Unlike some previous U.S. studies, we were able to assess geographic differences in 
maternal report of prenatal CHD diagnosis and found variation by NBDPS study site (and 
even greater variation within specific CHD types). In multivariable analysis, study site 
remained one of the strongest predictors of maternal report of prenatal CHD diagnosis and 
there remained a 3-fold difference between the lowest prenatal diagnosis study site and the 
highest. A study of the 15 referral centers in the U.S. Pediatric Heart Network from 
2005-2009 found that prenatal diagnosis rates for CHDs, even among these specialized 
centers, ranged from 59% to 82%.27 Referral centers that drew from larger population areas 
had significantly higher prenatal diagnosis rates. Prenatal diagnosis rates in the United 
Kingdom also varied significantly across postal codes and areas with higher prenatal 
diagnosis rates were more likely to detect defect types that exhibited abnormal outflow 
tracts, as well as abnormal four-chamber views.26 As controls enrolled in the NBDPS have 
been found to be representative of their respective source populations,28 it is unlikely that 
the geographic differences observed in our study are attributable to selection bias. Rather, 
geographic differences in prenatal diagnosis rates might be explained by differences in 
timely access to prenatal care, access to high-quality imaging technology or variation in 
proficiency of persons interpreting the ultrasounds and echocardiography. In Utah, the 
likelihood of prenatal CHD diagnosis was 1.6 times higher when the ultrasound was 
performed at a hospital and 10-times more likely when it was performed at a high-risk 
clinic.12 Increasing skill of the ultrasound reader and increasing number of ultrasounds also 
improved the likelihood of diagnosing a CHD prenatally.
Our prenatal diagnosis rate may be lower than previous studies for a number of reasons, 
some of which are limitations to NBDPS data in the context of this research question. First, 
the NBDPS inclusion criteria limit CHD cases to those without a recognized single-gene 
disorder or chromosomal abnormality, which might be less easily prenatally diagnosed. 
Previous studies reporting higher prenatal diagnosis rates did not note a similar restriction in 
the study population.10, 12, 27 Atrioventricular septal defects (AVSD) represent the extreme 
of the impact of this exclusion criterion. A recent comparison of AVSDs included in the 
NBDPS to those reported to their respective birth defects surveillance systems in Georgia, 
Iowa and Massachusetts found that 61% of all AVSD cases included in the surveillance 
system were excluded from the NBDPS because of chromosomal abnormalities and 1% 
were excluded because of single-gene disorders.29 However, many of the other CHD types 
under consideration in this study are not as frequently associated with genetic syndromes,30 
so the frequency of maternal report of prenatal detection may be more likely to reflect 
clinical practice. Second, we had a high proportion (99%) of live-born infants in our study 
sample, which is likely due to the stringent NBDPS criteria for confirmation of CHDs, as 
discussed previously. Other studies, both in Europe and in the United States, which have 
reported higher prenatal CHD diagnosis rates, including those approaching 50% in Paris 
from 1995-2000, have included more prenatally-diagnosed and terminated cases.2, 10, 26, 31
One might argue that the use of maternal self-report to define prenatal diagnosis could lead 
to an underestimate because mothers might not recall receiving a prenatal diagnosis. 
Ailes et al. Page 7
Prenat Diagn. Author manuscript; available in PMC 2015 June 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
However, the receipt of a CHD diagnosis is a stressful event in a pregnancy.32 A prenatal, as 
opposed to a postnatal diagnosis, carries with it the weight of having to make decisions 
about whether to continue the pregnancy and thus the recall of the event is likely to be 
accurate. Even among women with pregnancies unaffected by birth defects, Githens et al.'s 
small study found that 89% of 85 mothers accurately recalled receiving a prenatal ultrasound 
and 97% of 19 mothers accurately recalled receiving amniocentesis.33 Although time to 
interview was a significant predictor of prenatal diagnosis in our analysis, and we observed a 
decreasing frequency of maternal report of prenatal CHD diagnosis with increasing time to 
interview, this does not necessarily mean that mothers interviewed later were poorly 
recalling a prenatal diagnosis. Rather, it may be that those infants/fetuses that were 
diagnosed prenatally are captured earlier by their respective birth defects surveillance 
systems, and these mothers are contacted earlier by the NBDPS than mothers of infants/
fetuses diagnosed postnatally.
Still, the strengths of this analysis include the use of a large, multi-center case-control study, 
as opposed to studies restricted to single states or metropolitan areas; the blinded review of 
the maternal reports of the abnormalities identified on prenatal ultrasounds and fetal 
echocardiography; and the clinician verification of CHD diagnosis, as opposed to reliance 
solely on administrative coding to identified CHD cases.
Overall, we found that a low proportion (15%) of women with pregnancies affected by a 
non-syndromic CHD reported receiving a prenatal CHD diagnosis but the prevalence of 
prenatal diagnosis varied by both maternal and infant characteristics. Some of this variability 
may represent unmeasured differences in the quality of prenatal care received, differences in 
health literacy, or health system factors such as access to specialized prenatal care and/or 
fetal echocardiography. Countries which have observed marked increases in prenatal CHD 
detection rates have attributed such changes to improvements in sonographer training and 
availability of technology. For instance, in the Czech Republic, prenatal detection rates of a 
dozen types of CHD increased from 1986-1999 to 2000-2006, including from 31% to 96% 
for HLHS and 6% to 26% for transposition of the great arteries.34 Ensuring access to high-
quality prenatal care and adequate training of providers about prenatal diagnosis of CHDs 
has been shown to increase CHD prenatal diagnosis rates12,35 and including an assessment 
of outflow tracts in addition to a basic four chamber cardiac view can improve prenatal 
detection of CHD.36 However, it is unclear what proportion of obstetric practices are 
following guidelines put forth by the AUIM.37 Further work is warranted not only to 
understand the reasons for the observed variability in maternal reports of prenatal diagnosis 
but also to improve overall rates of prenatal diagnosis for CHD, since early diagnosis might 
improve survival and clinical outcomes.
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What's already known about this topic:
• Prenatal diagnosis of congenital heart defects (CHD) can lead to more timely 
interventions which may improve outcomes
What does this study add:
• 15% of mothers with a CHD-affected pregnancy reported receiving a prenatal 
diagnosis
• Prenatal diagnosis varied by infant/fetal characteristics such as CHD type, CHD 
complexity and presence of extracardiac defects; maternal factors including age, 
race/ethnicity, family history of CHD, plurality, prepregnancy diabetes, 
hypertension, and body mass index; and NBDPS study site and time to 
interview
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Figure 1. 
Frequency of maternal report of prenatal congenital heart defect diagnosis by defect type, 
for simple, isolated defectsa, National Birth Defects Prevention Study, 1998–2005 (n=4,455)
Note: Error bars represent exact 95% confidence intervals
a
 A case was categorized as having a “simple” heart defect if s/he had one heart defect or a 
well-defined constellation of defects such as hypoplastic left heart syndrome or tetralogy of 
Fallot and “isolated” if no extracardiac defects were present. For presentation purposes, we 
only present the frequencies for CHD types with ≥ 50 simple, isolated cases across all study 
sites.
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Figure 2. 
Frequency of maternal report of prenatal congenital heart defect diagnosis by defect type 
and study site, for select simple, isolated defects,a National Birth Defects Prevention Study, 
1998–2005
Note: Error bars represent exact 95% confidence intervals
a
 A case was categorized as having a “simple” heart defect if s/he had one heart defect or a 
well-defined constellation of defects such as hypoplastic left heart syndrome or tetralogy of 
Fallot and “isolated” if no extracardiac defects were present. For presentation purposes, we 
only present the frequencies for CHD types with > 300 simple, isolated cases and >10% 
maternal report of prenatal diagnosis across all study sites.
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Table
Maternal and infant characteristics associated with maternal report of prenatal CHD diagnosis, National Birth 
Defects Prevention Study, 1998-2005 (n=7,299)
Report of prenatal diagnosis
Characteristic N n(%) cPR (95% CI) aPR (95% CI)
CHD Complexity
    Simple (one heart defect) 5404 685 (12.7%) Reference Reference
    Two or more associated or complex heart defects 1895 412 (21.7%) 1.72 (1.54,1.92) 1.61 (1.44,1.81)
Presence of Extracardiac Defects
    No (isolated; no extracardiac defects) 6104 812 (13.3%) Reference Reference
    Yes (extracardiac defects present) 1195 285 (23.8%) 1.79 (1.59,2.02) 1.65 (1.46,1.87)
Year of Due Date
    1998 659 84 (12.7%) 0.78 (0.61,0.99) 0.79 (0.62,1.01)
    1999 782 114 (14.6%) 0.89 (0.72,1.11) 0.88 (0.71,1.10)
    2000 851 126 (14.8%) 0.91 (0.74,1.12) 0.90 (0.73,1.12)
    2001 880 126 (14.3%) 0.88 (0.71,1.08) 0.86 (0.70,1.07)
    2002 813 139 (17.1%) 1.05 (0.86,1.28) 0.95 (0.77,1.16)
    2003 959 146 (15.2%) 0.93 (0.76,1.14) 0.91 (0.74,1.11)
    2004 1246 181 (14.5%) 0.89 (0.74,1.08) 0.90 (0.74,1.09)
    2005 1109 181 (16.3%) Reference Reference
Family History of CHD (first degree relative)
    No 7047 1038 (14.7%) Reference Reference
    Yes 252 59 (23.4%) 1.59 (1.26,2.00) 1.47 (1.16,1.86)
Gestational Age
    Very preterm (<32 completed weeks) 613 84 (13.7%) 0.93 (0.76,1.15) 0.97 (0.78,1.20)
    Preterm (32-36 completed weeks) 1309 224 (17.1%) 1.17 (1.02,1.34) 1.09 (0.94,1.25)
    Term (≥ 37 completed weeks) 5376 789 (14.7%) Reference Reference
    Unknown/missing 1 0 (0%) NC NC
Plurality
    Singleton 6765 989 (14.6%) Reference Reference
    Twins or higher order gestation 525 106 (20.2%) 1.38 (1.15,1.65) 1.26 (1.03,1.54)
    Unknown/missing 9 2 (22.2%) NC NC
Maternal Race/Ethnicity
    Non-Hispanic white 4300 745 (17.3%) Reference Reference
    Non-Hispanic black 823 109 (13.2%) 0.76 (0.63,0.92) 0.83 (0.68,1.02)
    Hispanic 1741 166 (9.5%) 0.55 (0.47,0.65) 0.72 (0.59,0.89)
    Other 434 76 (17.5%) 1.01 (0.82,1.25) 0.97 (0.78,1.20)
    Unknown/missing 1 1 (100.0%) NC NC
Maternal Age (at delivery)
    <30 years 4336 542 (12.5%) Reference Reference
    >=30 years 2963 555 (18.7%) 1.50 (1.34,1.67) 1.13 (1.00,1.28)
Maternal Level of Education
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Report of prenatal diagnosis
Characteristic N n(%) cPR (95% CI) aPR (95% CI)
    0-12 years 3169 376 (11.9%) Reference Reference
    >12 years 4040 709 (17.5%) 1.48 (1.32,1.66) 1.14 (1.00,1.30)
    Unknown/missing 90 12 (13.3%) NC NC
Prepregnancy Maternal Body Mass Index (BMI)
    Underweight (<18.5 kg/m2) 384 60 (15.6%) 0.92 (0.72,1.17) 1.00 (0.79,1.28)
    Normal weight (18.5-24 kg/m2) 3492 596 (17.1%) Reference Reference
    Overweight (25-29 kg/m2) 1643 231 (14.1%) 0.82 (0.72,0.95) 0.87 (0.76,1.00)
    Obese (>=30 kg/m2) 1478 183 (12.4%) 0.73 (0.62,0.85) 0.78 (0.66,0.92)
    Unknown/missing 302 27 (8.9%) NC NC
Pregestational Diabetes
    None 6994 1016 (14.5%) Reference Reference
    Type 1 108 26 (24.1%) 1.66 (1.18,2.33) 1.57 (1.10,2.24)
    Type 2 138 41 (29.7%) 2.05 (1.57,2.66) 2.46 (1.86,3.24)
    Unknown/missing 59 14 (23.7%) NC NC
Hypertension (before or during index pregnancy)
    No 6100 951 (15.6%) Reference Reference
    Yes 1193 145 (12.2%) 0.78 (0.66,0.92) 0.81 (0.68,0.97)
    Unknown/missing 6 1 (16.7%) NC NC
Maternal Fertility Treatments
    No 6801 1002 (14.7%) Reference Reference
    Yes 426 84 (19.7%) 1.34 (1.10,1.63) 0.86 (0.68,1.08)
    Unknown/missing 72 11 (15.3%) NC NC
Number of Pregnancy Losses before this Pregnancy
    None 4681 679 (14.5%) Reference Reference
    One 1670 269 (16.1%) 1.11 (0.98,1.26) 1.05 (0.92,1.20)
    Two 606 84 (13.9%) 0.96 (0.77,1.18) 0.87 (0.70,1.07)
    More than two 338 65 (19.2%) 1.33 (1.05,1.67) 1.15 (0.90,1.45)
    Unknown/missing 4 0 (0.0%) NC NC
Pregnancy Intention
    Intended 4191 668 (15.9%) Reference Reference
    Mistimed/ambivalent 1700 247 (14.5%) 0.91 (0.80,1.04) 1.10 (0.95,1.27)
    Unwanted 1379 178 (12.9%) 0.81 (0.69,0.94) 0.96 (0.82,1.13)
    Unknown/missing 29 4 (13.8%) NC NC
Trimester of First Prenatal Care Visit
    1st 6121 947 (15.5%) Reference Reference
    2nd 895 117 (13.1%) 0.84 (0.71,1.01) 0.98 (0.82,1.18)
    3rd 66 7 (10.6%) 0.69 (0.34,1.38) 0.78 (0.41,1.47)
    Unknown/missing 217 26 (12.0%) NC NC
Time to Interview
    6 weeks-6 months 1652 341 (20.6%) Reference Reference
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Report of prenatal diagnosis
Characteristic N n(%) cPR (95% CI) aPR (95% CI)
    7-12 months 3132 477 (15.2%) 0.74 (0.65,0.84) 0.77 (0.67,0.88)
    13-18 months 1663 209 (12.6%) 0.61 (0.52,0.71) 0.71 (0.60,0.84)
    19-24 months 766 62 (8.1%) 0.39 (0.30,.51) 0.51 (0.39,0.68)
    Unknown/missing 86 8 (9.3%) NC NC
Study Site
    A 1188 84 (7.1%) Reference Reference
    B 1199 86 (7.2%) 1.01 (0.76,1.36) 1.19 (0.86,1.64)
    C 855 112 (13.1%) 1.85 (1.42,2.42) 1.96 (1.46,2.64)
    D 741 113 (15.2%) 2.16 (1.65,2.82) 2.18 (1.65,2.87)
    E 285 45 (15.8%) 2.23 (1.59,3.13) 2.16 (1.51,3.11)
    F 483 77 (15.9%) 2.25 (1.69,3.01) 2.13 (1.56,2.90)
    G 944 188 (19.9%) 2.82 (2.21,3.59) 2.64 (2.05,3.41)
    H 548 122 (22.3%) 3.15 (2.43,4.08) 2.71 (2.07,3.55)
    I 1056 270 (25.6%) 3.62 (2.87,4.55) 3.09 (2.42,3.94)
Bold indicates significance at < 0.05 level
CHD=congenital heart defect
NBDPS=National Birth Defects Prevention Study
cPR=crude prevalence ratio estimated from a Poisson regression model with robust error variance
aPR=adjusted prevalence ratio estimated from a Poisson regression model with robust error variance
CI=confidence interval
NC=not calculated
a
 Adjusted for all variables listed; excludes cases with at least one missing response
b
 A case was categorized as having a “simple” heart defect if s/he had one heart defect or a well-defined constellation of defects such as 
hypoplastic left heart syndrome or tetralogy of Fallot
c
 The study catchment area changed over time
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